Cover Image
市場調查報告書

Theraclone Sciences, Inc. - 產品平台分析

Theraclone Sciences, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 199818
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
Theraclone Sciences, Inc. - 產品平台分析 Theraclone Sciences, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 36 Pages
簡介

Theraclone Sciences, Inc. 是總公司設立於美國的生物科技企業,正在從事感染疾病,發炎,自體免疫疾病,癌症治療藥的開發。該公司的I-STAR技術是針對疾病原因的物質,鑑定產生人體記憶體B細胞機能的抗體之高通量篩檢技術。疾病對象領域有感染疾病,發炎等。

本報告提供Theraclone Sciences, Inc.的治療藥開發平台的現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Theraclone Sciences, Inc. 的基本資料

  • Theraclone Sciences, Inc. 概要
  • 主要資訊
  • 企業資料

Theraclone Sciences, Inc. :R&D概要

  • 主要的治療範圍

Theraclone Sciences, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Theraclone Sciences, Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Theraclone Sciences, Inc. :藥物簡介

  • TCN-032
  • Monoclonal Antibodies to Inhibit Hemagglutinin for Seasonal Influenza and Pandemic Influenza
  • PGT-121
  • Monoclonal Antibodies for Breast Cancer
  • Monoclonal Antibody for Asthma, COPD and Rhinovirus Infections
  • Monoclonal Antibody for Cancer
  • Monoclonal Antibody for Infectious Disease
  • Monoclonal Antibody for Infectious Disease Associated Cancers
  • Monoclonal Antibody for Klebsiella Pneumoniae Infections
  • Monoclonal Antibody for Undisclosed Target 2

Theraclone Sciences, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Theraclone Sciences, Inc. :最新的開發平台資訊

Theraclone Sciences, Inc. :開發暫停中的計劃

Theraclone Sciences, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07357CDB

Summary

Global Markets Direct's, 'Theraclone Sciences, Inc. - Product Pipeline Review - 2015', provides an overview of the Theraclone Sciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Theraclone Sciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Theraclone Sciences, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Theraclone Sciences, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Theraclone Sciences, Inc.'s pipeline products

Reasons to buy

  • Evaluate Theraclone Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Theraclone Sciences, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Theraclone Sciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Theraclone Sciences, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Theraclone Sciences, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Theraclone Sciences, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Theraclone Sciences, Inc. Snapshot
    • Theraclone Sciences, Inc. Overview
    • Key Information
    • Key Facts
  • Theraclone Sciences, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Theraclone Sciences, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Theraclone Sciences, Inc. - Pipeline Products Glance
    • Theraclone Sciences, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Theraclone Sciences, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Theraclone Sciences, Inc. - Drug Profiles
    • TCN-032
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Hemagglutinin for Seasonal Influenza and Pandemic Influenza
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PGT-121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Breast Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Asthma, COPD and Rhinovirus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Infectious Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Infectious Disease Associated Cancers
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Klebsiella Pneumoniae Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Undisclosed Target 2
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Theraclone Sciences, Inc. - Pipeline Analysis
    • Theraclone Sciences, Inc. - Pipeline Products by Target
    • Theraclone Sciences, Inc. - Pipeline Products by Route of Administration
    • Theraclone Sciences, Inc. - Pipeline Products by Molecule Type
    • Theraclone Sciences, Inc. - Pipeline Products by Mechanism of Action
  • Theraclone Sciences, Inc. - Recent Pipeline Updates
  • Theraclone Sciences, Inc. - Dormant Projects
  • Theraclone Sciences, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Theraclone Sciences, Inc., Key Information
  • Theraclone Sciences, Inc., Key Facts
  • Theraclone Sciences, Inc. - Pipeline by Indication, 2015
  • Theraclone Sciences, Inc. - Pipeline by Stage of Development, 2015
  • Theraclone Sciences, Inc. - Monotherapy Products in Pipeline, 2015
  • Theraclone Sciences, Inc. - Out-Licensed Products in Pipeline, 2015
  • Theraclone Sciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Theraclone Sciences, Inc. - Phase II, 2015
  • Theraclone Sciences, Inc. - Preclinical, 2015
  • Theraclone Sciences, Inc. - Discovery, 2015
  • Theraclone Sciences, Inc. - Pipeline by Target, 2015
  • Theraclone Sciences, Inc. - Pipeline by Route of Administration, 2015
  • Theraclone Sciences, Inc. - Pipeline by Molecule Type, 2015
  • Theraclone Sciences, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Theraclone Sciences, Inc. - Recent Pipeline Updates, 2015
  • Theraclone Sciences, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Theraclone Sciences, Inc. - Pipeline by Top 10 Indication, 2015
  • Theraclone Sciences, Inc. - Pipeline by Stage of Development, 2015
  • Theraclone Sciences, Inc. - Monotherapy Products in Pipeline, 2015
  • Theraclone Sciences, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top